There is one clinical trial.
An Open-label study for patients who completed the previous studies, PTI-125-02 or PTI-125-03. Additional new patients will be included for a total of 100 patients enrolled for this study.
Description: Biomarkers of AD pathology, neurodegeneration and neuroinflammation
Measure: Cerebrospinal fluid P-tau, neurofilament light chain, neurogranin, Total Tau, YKL-40, Abeta42 (pg/mL) Time: Screening to Month 12